No Data
Betta Pharmaceuticals (300558.SZ) and its holding subsidiary Xcovery pass the on-site inspection of the US FDA.
Gelonghui, August 20 | Betta Pharmaceutical (300558.SZ) announced that the company and its holding subsidiary Xdiscovery Holdings, Inc (hereinafter referred to as “Xdiscovery”) underwent clinical BIMO (Bioresearch Monitoring, Biological Research Monitoring) related PAI (Pre-Approval Inspection) on-site inspection by the US Food and Drug Administration (hereinafter referred to as “US FDA”) in May and June 2024, respectively, The active ingredient CMC (
At present, Betta Pharmaceuticals (300558.SZ) has no pharmaceutical product on the market or in development related to stem cell therapy projects.
Betta Pharmaceuticals (300558.SZ) stated on the investor interaction platform on August 16 that the company currently has no pharmaceuticals related to stem cell therapy on the market or under research and development.
Additional Considerations Required While Assessing Betta Pharmaceuticals' (SZSE:300558) Strong Earnings
Betta Pharmaceuticals Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Betta Pharmaceuticals: Summary of Half-Year Report in 2024.
Betta Pharmaceuticals: Half-year report for the year 2024.
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% LossNo Data
